Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab - Janssen Biotech

Next Previous
Drug Profile

Ustekinumab - Janssen Biotech

Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; Suterara

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Phase III Dermatomyositis; Polymyositis; Spondylarthritis; Vasculitis
  • Phase II Atopic dermatitis
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus

Most Recent Events

  • 05 Jun 2025 Janssen Research & Development completes the phase III UNIFI Jr trial in Ulcerative Colitis in USA, Belgium, Israel, Germany, Hungary, Japan, Poland, Russia the UK (IV, SC)(NCT04630028) (EudraCT2019-004224-38)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Psoriasis(In adolescents, In children, In infants) in USA (SC, Injection)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Psoriatic-arthritis(In adolescents, In children, In infants) in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top